Natco Pharma [NATCOPHARM] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison

Natco Pharma

NSE
Loading...

Sun Pharmaceutical

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Natco Pharma wins in 14 metrics, Sun Pharmaceutical wins in 6 metrics, with 0 ties. Natco Pharma appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricNatco PharmaSun PharmaceuticalBetter
P/E Ratio (TTM)9.0338.04Natco Pharma
Price-to-Book Ratio2.015.46Natco Pharma
Debt-to-Equity Ratio3.673.26Sun Pharmaceutical
PEG Ratio-0.32-1.95Sun Pharmaceutical
EV/EBITDA6.7624.18Natco Pharma
Profit Margin (TTM)38.62%19.29%Natco Pharma
Operating Margin (TTM)38.63%24.34%Natco Pharma
EBITDA Margin (TTM)38.63%24.34%Natco Pharma
Return on Equity24.77%15.08%Natco Pharma
Return on Assets (TTM)21.85%11.87%Natco Pharma
Free Cash Flow (TTM)$11.85B$119.44BSun Pharmaceutical
Dividend Yield0.92%1.26%Sun Pharmaceutical
1-Year Return-39.55%-16.50%Sun Pharmaceutical
Price-to-Sales Ratio (TTM)3.497.33Natco Pharma
Enterprise Value$132.71B$3,709.58BSun Pharmaceutical
EV/Revenue Ratio3.026.90Natco Pharma
Gross Profit Margin (TTM)82.47%79.58%Natco Pharma
Revenue per Share (TTM)$245$224Natco Pharma
Earnings per Share (Diluted)$94.75$43.22Natco Pharma
Beta (Stock Volatility)0.190.31Natco Pharma
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Natco Pharma vs Sun Pharmaceutical Stock Performance Analysis

Loading Price Chart...

Natco Pharma
Sun Pharmaceutical
Natco Pharma Stock Overview | Sun Pharmaceutical Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Natco Pharma-1.39%-0.36%-2.36%-1.73%2.93%-38.87%
Sun Pharmaceutical0.02%0.43%-1.79%-2.08%-8.84%-13.91%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Natco Pharma-39.55%41.00%-8.92%74.95%1,379.65%3,349.92%
Sun Pharmaceutical-16.50%71.52%220.99%82.62%701.37%2,516.34%

News Based Sentiment: Natco Pharma vs Sun Pharmaceutical

Natco Pharma

News based Sentiment: MIXED

September presented a mixed bag for Natco Pharma. While the positive FDA inspection is a significant win, disappointing earnings and waning investor confidence create headwinds. The Adcock Ingram acquisition remains a key catalyst, but its success is uncertain, making this a high-risk, high-reward investment.

View Natco Pharma News Sentiment Analysis

Sun Pharmaceutical

News based Sentiment: POSITIVE

September saw a surge of positive analyst ratings and price target increases for Sun Pharma, driven by strong growth projections and a robust financial position. While a technical sell signal emerged, the overall narrative is overwhelmingly positive, indicating a strengthening investment case and improved prospects for the company.

View Sun Pharmaceutical News Sentiment Analysis

Performance & Financial Health Analysis: Natco Pharma vs Sun Pharmaceutical

MetricNATCOPHARMSUNPHARMA
Market Information
Market Cap i₹153.24B₹3.94T
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i468,6662,018,311
90 Day Avg. Volume i420,9912,394,082
Last Close₹842.30₹1,627.40
52 Week Range₹726.80 - ₹1,505.00₹1,553.05 - ₹1,960.35
% from 52W High-44.03%-16.98%
All-Time High₹1,639.00 (Sep 09, 2024)₹1,960.35 (Sep 30, 2024)
% from All-Time High-48.61%-16.98%
Growth Metrics
Quarterly Revenue Growth-0.03%0.10%
Quarterly Earnings Growth-0.28%-0.20%
Financial Health
Profit Margin (TTM) i0.39%0.19%
Operating Margin (TTM) i0.39%0.24%
Return on Equity (TTM) i0.25%0.15%
Debt to Equity (MRQ) i3.673.26
Cash & Liquidity
Book Value per Share (MRQ)₹424.69₹300.99
Cash per Share (MRQ)₹139.41₹108.88
Operating Cash Flow (TTM) i₹19.26B₹110.84B
Levered Free Cash Flow (TTM) i₹18.85B₹109.29B
Dividends
Last 12-Month Dividend Yield i0.92%1.26%
Last 12-Month Dividend i₹8.00₹21.00

Valuation & Enterprise Metrics Analysis: Natco Pharma vs Sun Pharmaceutical

MetricNATCOPHARMSUNPHARMA
Price Ratios
P/E Ratio (TTM) i9.0338.04
Forward P/E i20.7350.31
PEG Ratio i-0.32-1.95
Price to Sales (TTM) i3.497.33
Price to Book (MRQ) i2.015.46
Market Capitalization
Market Capitalization i₹153.24B₹3.94T
Enterprise Value i₹132.71B₹3.71T
Enterprise Value Metrics
Enterprise to Revenue i3.026.90
Enterprise to EBITDA i6.7624.18
Risk & Other Metrics
Beta i0.190.31
Book Value per Share (MRQ) i₹424.69₹300.99

Financial Statements Comparison: Natco Pharma vs Sun Pharmaceutical

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)NATCOPHARMSUNPHARMA
Revenue/Sales i₹13.29B₹137.86B
Cost of Goods Sold i₹2.33B₹28.15B
Gross Profit i₹10.96B₹109.71B
Research & Development iN/AN/A
Operating Income (EBIT) i₹5.13B₹33.72B
EBITDA i₹6.33B₹47.66B
Pre-Tax Income i₹5.72B₹31.73B
Income Tax i₹916.00M₹8.70B
Net Income (Profit) i₹4.80B₹22.93B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)NATCOPHARMSUNPHARMA
Cash & Equivalents i₹1.20B₹102.69B
Total Current Assets i₹52.70B₹526.24B
Total Current Liabilities i₹9.44B₹181.94B
Long-Term Debt i₹46.00M₹3.58B
Total Shareholders Equity i₹76.12B₹724.86B
Retained Earnings i₹62.47B₹578.62B
Property, Plant & Equipment i₹474.00M₹100.36B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)NATCOPHARMSUNPHARMA
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNATCOPHARMSUNPHARMA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i468,6662,018,311
Average Daily Volume (90 Day) i420,9912,394,082
Shares Outstanding i179.11M2.40B
Float Shares i83.17M1.04B
% Held by Insiders i0.51%0.56%
% Held by Institutions i0.13%0.25%

Dividend Analysis & Yield Comparison: Natco Pharma vs Sun Pharmaceutical

MetricNATCOPHARMSUNPHARMA
Last 12-Month Dividend i₹8.00₹21.00
Last 12-Month Dividend Yield i0.92%1.26%
3-Year Avg Annual Dividend i₹6.50₹14.67
3-Year Avg Dividend Yield i0.24%0.46%
3-Year Total Dividends i₹19.50₹44.00
Ex-Dividend DateAug 19, 2025Jul 07, 2025